Daily Investment Ideas

1. NUE

Pros of Investing in NUE:

- Experienced leadership with long tenure

- Financials are in good health with strong cash flow and low debt/equity ratio

- High dividend yield of 2.03%

- Low beta of 1.58

- Low price-to-earnings ratio of 5.91

- Positive earnings growth and revenue growth

- High return on assets and equity

- Strong gross margins and operating margins

Cons of Investing in NUE:

- Low payout ratio of 7.9%

- Low dividend yield compared to 5 year average of 2.37%

- Low price to book ratio of 1.99

- High short interest ratio of 3.89

2. DHI

Pros of Investing in DHI:

- D.R. Horton, Inc. is a well-established homebuilding company with operations in 33 states

- Its leadership team has extensive experience in the industry, with the CEO and CFO having more than 25 years of combined experience

- DHI has a low payout ratio of 0.0641, indicating that it is able to retain more of its profits for reinvestment

- DHI has a low Beta of 1.536971, indicating that it is less volatile than the market

- DHI has a trailing PE of 7.7927074, indicating that it is undervalued compared to its peers

- DHI has a dividend rate of 1.0 and a dividend yield of 0.0088

- DHI has a strong balance sheet with a total cash of $2.76 billion and total debt of $6.03 billion

Cons of Investing in DHI:

- DHI has experienced a decline in its earnings growth, with a drop of -0.323 over the last year

- DHI’s revenue growth has also been declining, with a drop of -0.003 over the last year

- DHI has a high debt to equity ratio of 28.576, indicating that it has a high level of debt relative to its equity

- DHI’s share price is highly correlated with the market, with a Beta of 1.536971

3. MRNA

Pros of Investing in MRNA:

• Experienced executive team with significant industry experience

• High revenue growth in recent years

• High gross and operating margins

• High return on assets and equity

• Positive free cash flow

• Low debt-to-equity ratio

• Low payout ratio

Cons of Investing in MRNA:

• High beta of 1.7

• Low trailing and forward PE ratios

• Low price-to-sales ratio

• Low recommendation mean of 2.4